MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien Earnings Recaps

MRK.DE Health Care 1 recap
Next earnings: March 4, 2027 (estimated) · full calendar
Q3 2026 Nov 14, 2026

Merck reported 5.1% organic sales growth in Q3 and raised full-year guidance; the shares fell 1.3%, a roughly flat reaction. Growth in Life Science and Electronics was tempered by accelerating Mavenclad erosion in U.S. Specialty Care and expected further headwinds in consumer electronics.

Key takeaways
  • Group organic sales growth accelerated to 5.1%, with significant contributions from Life Science and Electronics.
  • Life Science’s Process Solutions grew 10.5% organically; Discovery Solutions recorded modest growth as markets stabilized.
  • Electronics organic growth reached 13%, led by Semiconductor Solutions at 19%; Optronics was broadly stable, with consumer electronics headwinds expected to intensify.
  • Healthcare sales improved sequentially. Rare Diseases contributed to organic growth for the first time, while Specialty Care faced faster U.S. Mavenclad erosion.
  • Management raised full-year guidance again and cited strong cash generation and an improved leverage ratio; the transcript excerpt does not provide the updated guidance figures.